Investigating how certain cell signaling affects kidney disease progression
The role of maladaptive VEGFR2 signaling in renal stroma for chronic kidney disease
This study is looking at how sudden kidney damage can lead to long-term kidney problems, and it aims to find out how certain signals between kidney cells can help us understand this better, which could eventually lead to new ways to prevent chronic kidney disease for people who have had acute kidney injury.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11097352 on NIH RePORTER |
What this research studies
This research focuses on understanding how acute kidney injury (AKI) can lead to chronic kidney disease (CKD) by examining the role of specific cell signaling pathways. The study will explore the interactions between different types of kidney cells, particularly how the signaling from vascular endothelial growth factor receptor 2 (VEGFR2) influences inflammation and kidney damage. By using advanced techniques like RNA sequencing, researchers aim to identify the molecular mechanisms involved in this process, which could lead to new therapeutic strategies for preventing CKD in patients who have experienced AKI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acute kidney injury and are at risk of developing chronic kidney disease.
Not a fit: Patients with chronic kidney disease not related to acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent the progression from acute kidney injury to chronic kidney disease, improving patient outcomes.
How similar studies have performed: Previous research has shown that targeting VEGFR2 can effectively block the progression of chronic kidney disease, indicating a promising avenue for further exploration.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Chiba, Takuto Greco — University of Pittsburgh at Pittsburgh
- Study coordinator: Chiba, Takuto Greco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.